Drug Profile
Research programme: HBV RNA destabilisers - Arbutus Biopharma
Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Baruch S. Blumberg Institute; Drexel University College of Medicine
- Developer Arbutus Biopharma
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis B virus replication inhibitors; Viral antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Hepatitis B
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for research development in Hepatitis-B in USA (PO)
- 05 Nov 2019 Research programme: HBV RNA destabilisers - Arbutus Biopharma is available for licensing as of 05 Nov 2019. http://www.arbutusbio.com/partners/partnering-licensing-opportunities.php
- 06 May 2019 Arbutus Biopharma expects to get the 2nd generation RNA destabilizer candidate (CCN) nominated for development by the end of 2019